Status: Recruiting
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Participants needed: 67
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Novelty Nobility, Inc.Updated: Sep 23, 2025Locations: 5
Eligibility criteria
Histologically or cytologically confirmed locally advanced, metastatic, and/or u... [+13]
Has received prior therapy with a c-Kit agent (except GIST subjects). [+12]